Callos Andrew's Form 4 filing
Cytokinetics Inc (CYTK) · filed Jun 1, 2026
- Accession no.
- 0001061983-26-000065
- Filed
- Jun 1, 2026
- Trade date
- Jun 1, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.11M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Callos AndrewCIK 0001852129 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseAcquired | +15,000 | $23.26 | +$348,900 | 73,555 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −15,000 | $74.08 | −$1,111,200 | 58,555 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 39,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.